First Trust Advisors LP raised its holdings in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 26.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 813,647 shares of the biopharmaceutical company’s stock after acquiring an additional 169,331 shares during the quarter. First Trust Advisors LP’s holdings in Agios Pharmaceuticals were worth $46,516,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of AGIO. Alliancebernstein L.P. boosted its position in Agios Pharmaceuticals by 16.3% in the 2nd quarter. Alliancebernstein L.P. now owns 21,742 shares of the biopharmaceutical company’s stock valued at $1,119,000 after buying an additional 3,050 shares during the period. Teachers Advisors LLC boosted its position in Agios Pharmaceuticals by 54.4% in the 2nd quarter. Teachers Advisors LLC now owns 46,733 shares of the biopharmaceutical company’s stock valued at $2,404,000 after buying an additional 16,475 shares during the period. Ameriprise Financial Inc. boosted its position in Agios Pharmaceuticals by 21.9% in the 2nd quarter. Ameriprise Financial Inc. now owns 49,994 shares of the biopharmaceutical company’s stock valued at $2,572,000 after buying an additional 8,965 shares during the period. Northern Trust Corp boosted its position in Agios Pharmaceuticals by 31.3% in the 2nd quarter. Northern Trust Corp now owns 232,802 shares of the biopharmaceutical company’s stock valued at $11,977,000 after buying an additional 55,560 shares during the period. Finally, California Public Employees Retirement System boosted its position in Agios Pharmaceuticals by 2.3% in the 2nd quarter. California Public Employees Retirement System now owns 34,900 shares of the biopharmaceutical company’s stock valued at $1,796,000 after buying an additional 800 shares during the period. 82.74% of the stock is owned by institutional investors.
In related news, major shareholder Corp /De/ Celgene purchased 851,154 shares of the business’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were purchased at an average cost of $67.00 per share, for a total transaction of $57,027,318.00. Following the purchase, the insider now directly owns 1,374,599 shares of the company’s stock, valued at $92,098,133. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Christopher Bowden sold 2,000 shares of Agios Pharmaceuticals stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.75, for a total transaction of $157,500.00. Following the sale, the insider now owns 2,881 shares in the company, valued at $226,878.75. The disclosure for this sale can be found here. Insiders sold a total of 183,114 shares of company stock worth $13,866,025 over the last 90 days. Company insiders own 5.43% of the company’s stock.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.65) by ($0.16). Agios Pharmaceuticals had a negative net margin of 731.60% and a negative return on equity of 76.67%. The firm had revenue of $9.80 million during the quarter, compared to analyst estimates of $12.65 million. During the same quarter in the previous year, the business posted ($1.34) earnings per share. Agios Pharmaceuticals’s revenue for the quarter was down 56.7% compared to the same quarter last year. research analysts forecast that Agios Pharmaceuticals Inc will post -6.15 EPS for the current year.
Several brokerages have commented on AGIO. Credit Suisse Group raised their price target on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. Oppenheimer cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $84.00 price objective on the stock in a report on Tuesday, January 16th. Canaccord Genuity set a $90.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 12th. Finally, ValuEngine upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Agios Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $85.50.
COPYRIGHT VIOLATION WARNING: This story was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.chaffeybreeze.com/2018/02/18/first-trust-advisors-lp-acquires-169331-shares-of-agios-pharmaceuticals-inc-agio.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals Inc (NASDAQ:AGIO).
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.